# Panobinostat/Velcade in Multiple Myeloma

> **NCT00891033** · PHASE1 · TERMINATED · sponsor: **University of Arkansas** · enrollment: 12 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib (Velcade)
- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT00891033
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** This study was terminated because the drug company stopped making the study drug
- **Last updated:** 2015-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891033, "Panobinostat/Velcade in Multiple Myeloma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00891033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*